Respiratory drugs
These companies make drugs for lung conditions such as asthma, COPD, bronchiectasis and chronic cough.
−20.5%
over 1 year · S&P 500 +11.6%
Key indicators
Health
51 / 100
Fragile
Solid
Price
P/E 16
Cheap
Expensive
Up over 1 year
6 of 11
Volatility
59%
Calm
Choppy
Health and price: against the other tags.
Key indicators
When a figure has a bar, the marker places it among its peers, and the further right it sits, the more the figure beats the others. Green marks the best third, red the weakest and white anything in between. Some figures stay white wherever they sit, like price, pace or holding time, because neither side is better there.
The 16 companies
INSM
−37.7%
KYMR
+100.8%
Size: weight in the tag. Color: move over the period.
See all companies
See all companies
I
Insmed
INSM
55.7%
−37.7%
K
Kymera Therapeutics
KYMR
22.8%
+100.8%
T
Trevi Therapeutics
TRVI
4.1%
+15.2%
Z
Zymeworks
ZYME
3.8%
+35.5%
G
Generate Biomedicines
GENB
3.7%
A
Avalyn Pharma
AVLN
2.9%
I
Innoviva
INVA
2.8%
−14.6%
S
Savara
SVRA
2.4%
+12.6%
C
Contineum Therapeutics
CTNM
0.9%
−14.0%
A
Arcturus Therapeutics
ARCT
0.5%
+2.8%
U
Upstream Bio
UPB
0.4%
−88.3%
A
AgomAb Therapeutics
AGMB
A
AstraZeneca
AZN
B
Bambusa Therapeutics
BBTX
G
GSK
GSK
+8.6%
S
Sanofi
SNY
−3.1%